Coronavirus

Brazilian Supreme Court set to decide whether tens of thousands of patents live or die

Up to 30,000 individual grants are at risk as the country’s highest court decides whether to retroactively apply a landmark ruling it handed down last week

Brazilian Supreme Court set to decide whether tens of thousands of patents live or die
Biden’s backing for the covid vaccine IP waiver should concern all rights owners
8 May 2021

Biden’s backing for the covid vaccine IP waiver should concern all rights owners

This week’s unprecedented move raises a series of worrying questions and puts in doubt the administration’s commitment to fostering innovative activity

Biden backs covid-19 IP waiver in historic US policy shift
6 May 2021

Biden backs covid-19 IP waiver in historic US policy shift

Landmark move suggests realignment in America’s domestic and international healthcare IP stance

Latest

View all
4 May 2021

Brazilian Senate passes compulsory covid-19 know-how licensing bill

Vaccine owners may be forced to hand over trade secrets or have their patents cancelled under legislation endorsed by the upper house of the country’s Congress Read more

26 Apr 2021

Get smarter about covid patents or pay the price

On World IP Day it's time to get a few things straight about where the real problems in getting jabs to those who need them really lie Read more

20 Apr 2021

TRIPS covid vaccine IP waiver proposal fails to address crucial questions

President Biden and other leaders are coming under pressure to agree a suspension of IP rights, but a key point has been missed Read more

13 Apr 2021

Brazil suspends drug patent extensions and reschedules key Supreme Court hearing for tomorrow

Long-running constitutional challenge putting 40% of patents at-risk set to be resolved, but further delays are possible Read more

News

View all
2 Mar 2021

Negotiating patent licensing agreements during a pandemic

Co-published - Although some major deals in the semiconductor space have been concluded over the last year, respondents to a survey on virtual negotiations see major difficulties in online discussions Read more

19 Nov 2020

Your guide to covid-19 vaccine stakeholders’ IP strategies

IAM examines the approaches taken by – and the issues facing – the leading companies in the race to find effective coronavirus inoculations Read more

16 Nov 2020

Moderna's covid vaccine is promising news, but IP issues may mean the financial windfall it enjoys are limited

A major PTAB defeat and uncertainties around US government funding cast a royalties shadow over the company's ability to monetise the breakthrough Read more

9 Nov 2020

Pfizer’s covid vaccine found 90% effective, but raises IP questions

Company CEO proclaims “a great day for science and humanity”, but there are patent, know-how and data uncertainties to overcome Read more

Analysis

View all
7 Apr 2021

Relaxing patent rights in a pandemic is a win for innovators and the public

The long read: Womble Bond Dickinson’s Ben Bourke takes a deep dive into how life science companies have handled their IP portfolios over the covid-19 pandemic – in particular Moderna Therapeutics’ pledge not to enforce patents relating to its vaccine – and examines how such adjustments can prepare the ground for future inventions Read more

25 Mar 2021

Europe is seeing a boom in pharma and biotech patenting

A surge in life sciences applications offset a disappointing performance in other areas, the latest EPO statistics suggest Read more

16 Mar 2021

We worked at triple speed on vaccine patent strategy to help the world, says BioNTech IP chief

“You could go through a practice of 30 years, never experiencing what we have just been through in a year,” says Julie Anne Gillespie in exclusive interview alongside colleague James Ryan Read more

9 Mar 2021

Covid-19 patent landscape confusion is a big concern for life sciences organisations

Providing new insights into recent filings, but patent landscape uncertainties may pose dangers in the wake of the pandemic Read more

Insights

View all
8 Jun 2020

From French fancy to global community – celebrating 100 issues of IAM 

Founder and editor in chief Joff Wild looks back on 17 years of IAM Read more

Find an expert